+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Management of oral anticoagulants in the treatment of venous thromboembolism



Management of oral anticoagulants in the treatment of venous thromboembolism



European Journal of Internal Medicine 12(2): 75-85



Venous thromboembolism still represents a major public health problem. After initial heparin therapy, oral anticoagulants are the treatment most often used. Bleeding is the major risk of such a therapy. This review of the literature emphasises the practical aspects of the clinical management of oral anticoagulant therapy, such as initiation, monitoring, interaction, withdrawal, optimal duration, bleeding complications and non-haemorrhagic adverse reactions.

(PDF emailed within 0-6 h: $19.90)

Accession: 046614508

Download citation: RISBibTeXText

PMID: 11297909

DOI: 10.1016/s0953-6205(01)00120-0


Related references

Oral anticoagulants in the management of venous thromboembolism. Nature Reviews Cardiology 10(7): 397-409, 2013

New oral anticoagulants to revolutionise venous thromboembolism (VTE) management. Journal of Orthopaedic Nursing 13(4): 165-171, 2009

The role of direct oral anticoagulants in the management of venous thromboembolism. American Journal of Managed Care 23(20 Suppl): S383-S390, 2018

New oral anticoagulants in the management of venous thromboembolism: a major advance?. European Journal of Vascular and Endovascular Surgery 48(5): 487-488, 2015

New oral anticoagulants for the treatment of venous thromboembolism. Best Practice & Research. Clinical Haematology 26(2): 151-161, 2014

New oral anticoagulants for treatment of venous thromboembolism. Deutsche Medizinische Wochenschrift 136(22): 1162-1164, 2011

Oral anticoagulants for the treatment of venous thromboembolism. Bailliere's Clinical Haematology 11(3): 639-661, 1999

New oral anticoagulants in the treatment of venous thromboembolism. Presse Medicale 42(9 Pt 1): 1232-1238, 2013

New oral anticoagulants for the treatment ofA venous thromboembolism. 2013

Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics 20(5): 490-500, 2016

Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2018

Management of Venous Thromboembolism in the Elderly: A Review of the Non-Vitamin K Oral Anticoagulants. Consultant Pharmacist 33(5): 248-261, 2018

Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism. Heart 102(12): 975-983, 2016

A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism. American Journal of the Medical Sciences 352(1): 92-106, 2016

Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. Blood Reviews 28(1): 1-8, 2014